In the following tables, revenues are disaggregated by category, sales by geographic market and sales by product data. The following breaks down revenues into the following categories (in thousands):

	Years Ended
	2019		2018		2017
Non-consignment sales	$	132,716	$	106,338	$	74,163
Consignment sales		17,469		17,616		16,448
Total net sales	$	150,185	$	123,954	$	90,611

The Company markets and sells its products in more than 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales in that country exceed 10% of consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):

	Years Ended
	2019		2018		2017
Domestic	$	8,106	$	7,316	$	7,894
Foreign:
China⁽¹⁾		64,820		46,070		24,473
Japan		26,881		23,151		18,125
Other⁽²⁾		50,378		47,417		40,119
Total foreign sales		142,079		116,638		82,717
Total net sales	$	150,185	$	123,954	$	90,611

Note 17 — Disaggregation of Revenues, Geographic Sales and Product Sales (Continued)

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes the operating decisions and allocates resources based upon the consolidated operating results, therefore, the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are IOLs used in cataract surgery and ICLs used in refractive surgery. The composition of the Company’s net sales by product line was as follows (in thousands):

	Years Ended
	2019		2018		2017
ICLs	$	129,322	$	101,082	$	68,325
Other product sales
IOLs		15,689		16,193		17,258
Other surgical products		5,174		6,679		5,028
Total other product sales		20,863		22,872		22,286
Total net sales	$	150,185	$	123,954	$	90,611

The Company sells its products internationally, which subjects the Company to several potential risks, including fluctuating exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, U.S. and foreign export and import duties and tariffs, and political instability